Drugs / CD19/CD22-CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03241940 | Oct 2017 → Apr 2025 overdue | B-cell acute lymphoblastic leukemia, adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia | Stanford University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22-CAR T cells | “Given CD19/CD22-CAR T cells IV” NCT03241940 ↗ |
| Modality | Cell therapy | “A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells” NCT03241940 ↗ |
| Route | Intravenous | “CD19/CD22-CAR T cells IV over 10-20 minutes” NCT03241940 ↗ |